Small molecule therapy is a critical component of targeted anticancer treatment, with tyrosine kinase inhibitors (TKIs) being the first compounds to treat the clonal Chronic Myelogenous Leukaemia (CML) translocation t (9;22) (q34; q11) effectively since 2001. TKIs, such as imatinib, have improved the 10-year survival rate of CML patients to 80%. They bind the kinase and inhibit downstream signaling pathways. However, therapy failure may be seen in 20-25% of CML patients due to intolerance or inadequacy related to dependent or independent mechanisms. This review aimed to summarize current treatment options involving TKIs, resistance mechanisms and the prospective approaches to overcome TKI resistance. We highlight -dependent mechanisms of ...
Chronic myeloid leukemia (CML) is characterized by the accumulation of Philadelphia chromosome-posit...
Treatments for chronic myeloid leukemia (CML) represent a success story in mo-lecular medicine. The ...
Chronic myelogenous leukaemia (CML) is characterised by a t(9;22)(q34;q11) translocation, which prod...
Current treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI) is effect...
Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with a characteristic chr...
Chronic myeloid leukemia is a stem cell-initiated but progenitor-driven disease induced by the BCR–A...
Deregulated activity of BCR-ABL1, a nonreceptor tyrosine kinase encoded by the fusion gene resulting...
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of patients with chronic myeloid...
© 2021 by the authors.Resistance to targeted therapies is a complex and multifactorial process that ...
Chronic myelogenous leukaemia (CML) is characterised by a t(9;22)(q34;q11) translocation, which prod...
Not all chronic myeloid leukemia (CML) patients are cured with tyrosine kinase inhibitors (TKIs), an...
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder characterized by the reci...
The treatment of chronic myeloid leukemia (CML) has been radically changed by the approval of tyrosi...
Chronic myeloid leukemia is a malignancy of bone marrow that affects white blood cells. There is str...
BACKGROUND: Chronic myeloid leukaemia (CML) is characterised by the presence of a fusion driver onco...
Chronic myeloid leukemia (CML) is characterized by the accumulation of Philadelphia chromosome-posit...
Treatments for chronic myeloid leukemia (CML) represent a success story in mo-lecular medicine. The ...
Chronic myelogenous leukaemia (CML) is characterised by a t(9;22)(q34;q11) translocation, which prod...
Current treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI) is effect...
Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with a characteristic chr...
Chronic myeloid leukemia is a stem cell-initiated but progenitor-driven disease induced by the BCR–A...
Deregulated activity of BCR-ABL1, a nonreceptor tyrosine kinase encoded by the fusion gene resulting...
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of patients with chronic myeloid...
© 2021 by the authors.Resistance to targeted therapies is a complex and multifactorial process that ...
Chronic myelogenous leukaemia (CML) is characterised by a t(9;22)(q34;q11) translocation, which prod...
Not all chronic myeloid leukemia (CML) patients are cured with tyrosine kinase inhibitors (TKIs), an...
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder characterized by the reci...
The treatment of chronic myeloid leukemia (CML) has been radically changed by the approval of tyrosi...
Chronic myeloid leukemia is a malignancy of bone marrow that affects white blood cells. There is str...
BACKGROUND: Chronic myeloid leukaemia (CML) is characterised by the presence of a fusion driver onco...
Chronic myeloid leukemia (CML) is characterized by the accumulation of Philadelphia chromosome-posit...
Treatments for chronic myeloid leukemia (CML) represent a success story in mo-lecular medicine. The ...
Chronic myelogenous leukaemia (CML) is characterised by a t(9;22)(q34;q11) translocation, which prod...